318 related articles for article (PubMed ID: 1377948)
61. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
Zvi A; Feigelson DJ; Hayek Y; Anglister J
Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
[TBL] [Abstract][Full Text] [Related]
62. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
[TBL] [Abstract][Full Text] [Related]
63. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
[TBL] [Abstract][Full Text] [Related]
64. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
[TBL] [Abstract][Full Text] [Related]
65. Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.
Rubinstein A; Goldstein H; Pettoello-Mantovani M; Mizrachi Y; Bloom BR; Furer E; Althaus B; Que JU; Hasler T; Cryz SJ
AIDS; 1995 Mar; 9(3):243-51. PubMed ID: 7755912
[TBL] [Abstract][Full Text] [Related]
66. Epitope specificity, antibody-dependent cellular cytotoxicity, and neutralizing activity of antibodies to human immunodeficiency virus type 1 in autoimmune MRL/lpr mice.
Lombardi V; Placido R; Scarlatti G; Romiti ML; Mattei M; Mariani F; Poccia F; Rossi P; Colizzi V
J Infect Dis; 1993 Jun; 167(6):1267-73. PubMed ID: 7684755
[TBL] [Abstract][Full Text] [Related]
67. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.
White-Scharf ME; Potts BJ; Smith LM; Sokolowski KA; Rusche JR; Silver S
Virology; 1993 Jan; 192(1):197-206. PubMed ID: 7685962
[TBL] [Abstract][Full Text] [Related]
68. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
[TBL] [Abstract][Full Text] [Related]
69. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
[TBL] [Abstract][Full Text] [Related]
70. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.
Moore JP; Trkola A; Korber B; Boots LJ; Kessler JA; McCutchan FE; Mascola J; Ho DD; Robinson J; Conley AJ
J Virol; 1995 Jan; 69(1):122-30. PubMed ID: 7527082
[TBL] [Abstract][Full Text] [Related]
71. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.
Schreiber M; Petersen H; Wachsmuth C; Müller H; Hufert FT; Schmitz H
J Virol; 1994 Jun; 68(6):3908-16. PubMed ID: 8189527
[TBL] [Abstract][Full Text] [Related]
72. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
[TBL] [Abstract][Full Text] [Related]
73. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
[TBL] [Abstract][Full Text] [Related]
74. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
Fung MS; Sun CR; Gordon WL; Liou RS; Chang TW; Sun WN; Daar ES; Ho DD
J Virol; 1992 Feb; 66(2):848-56. PubMed ID: 1370558
[TBL] [Abstract][Full Text] [Related]
75. Mapping of two new human B-cell epitopes on HIV-1 gp120.
Kusk P; Holmbäck K; Lindhardt BO; Hulgaard EF; Bugge TH
AIDS; 1992 Dec; 6(12):1451-6. PubMed ID: 1283518
[TBL] [Abstract][Full Text] [Related]
76. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
[TBL] [Abstract][Full Text] [Related]
77. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
[TBL] [Abstract][Full Text] [Related]
78. Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS.
Page M; Vella C; Corcoran T; Dilger P; Ling C; Heath A; Thorpe R
AIDS; 1992 May; 6(5):441-6. PubMed ID: 1616648
[TBL] [Abstract][Full Text] [Related]
79. Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals.
Kenealy WR; Matthews TJ; Ganfield MC; Langlois AJ; Waselefsky DM; Petteway SR
AIDS Res Hum Retroviruses; 1989 Apr; 5(2):173-82. PubMed ID: 2469449
[TBL] [Abstract][Full Text] [Related]
80. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.
Visciano ML; Tuen M; Gorny MK; Hioe CE
Virology; 2008 Mar; 372(2):409-20. PubMed ID: 18054978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
